FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor...

Details FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor... FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor...

2006-04-25

2006-04-25

Murphy, Joseph (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S350000, C435S069100, C435S320100, C435S325000, C536S023500

Reexamination Certificate

active

07034105

ABSTRACT:
The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.

REFERENCES:
patent: 4543439 (1985-09-01), Fracketton, Jr. et al.
patent: 4652639 (1987-03-01), Stabinsky
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5185438 (1993-02-01), Lemischka
patent: 5198359 (1993-03-01), Taniguchi et al.
patent: 5231001 (1993-07-01), Kaplan et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5270458 (1993-12-01), Lemischka
patent: 5283354 (1994-02-01), Lemischka
patent: 5367057 (1994-11-01), Lemischka
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5693762 (1997-12-01), Queen et al.
patent: 5700822 (1997-12-01), Hirth et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5747651 (1998-05-01), Lemischka
patent: 5750078 (1998-05-01), Shitara et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5763733 (1998-06-01), Whitlow et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5798097 (1998-08-01), McKenzie et al.
patent: 5807548 (1998-09-01), Shitara et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 5952199 (1999-09-01), Davis-Smyth et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6100071 (2000-08-01), Davis-Smyth
patent: 6107046 (2000-08-01), Alitalo et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6331302 (2001-12-01), Bennett et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 6383486 (2002-05-01), Davis-Smyth
patent: 6403088 (2002-06-01), Alitalo
patent: 6451764 (2002-09-01), Lee et al.
patent: 6576608 (2003-06-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6673343 (2004-01-01), Bennett et al.
patent: 6689580 (2004-02-01), Achen et al.
patent: 6730658 (2004-05-01), Alitalo et al.
patent: 2001/0038842 (2001-11-01), Achen et al.
patent: 2002/0065218 (2002-05-01), Achen et al.
patent: 2002/0102260 (2002-08-01), Achen et al.
patent: 2002/0120123 (2002-08-01), Rosen et al.
patent: 2002/0123481 (2002-09-01), Oliviero
patent: 2002/0127222 (2002-09-01), Achen et al.
patent: 2002/0146420 (2002-10-01), Bennett et al.
patent: 2002/0151489 (2002-10-01), Gavereaux et al.
patent: 2002/0182683 (2002-12-01), Hu et al.
patent: 2003/0008357 (2003-01-01), Hu et al.
patent: 2003/0028007 (2003-02-01), Hu et al.
patent: 2003/0091567 (2003-05-01), Alitalo et al.
patent: 2003/0092604 (2003-05-01), Alitalo et al.
patent: 2003/0125537 (2003-07-01), Achen et al.
patent: 2003/0166523 (2003-09-01), Achen et al.
patent: 2003/0166547 (2003-09-01), Oliviero
patent: 2003/0166873 (2003-09-01), Lee et al.
patent: 2003/0180294 (2003-09-01), DeVries
patent: 2003/0211101 (2003-11-01), Wise et al.
patent: 2003/0211988 (2003-11-01), Epstein
patent: 2003/0215921 (2003-11-01), Coleman
patent: 2004/0037820 (2004-02-01), Alitalo et al.
patent: 0 325 224 (1989-07-01), None
patent: 0935001 (1999-08-01), None
patent: WO 90/14425 (1990-11-01), None
patent: WO 92/14748 (1992-03-01), None
patent: WO 92/13867 (1992-08-01), None
patent: WO 93/14124 (1993-07-01), None
patent: WO 93/15201 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 95/24473 (1995-09-01), None
patent: WO 95/33772 (1995-12-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/12972 (1997-04-01), None
patent: WO 98/02543 (1998-01-01), None
patent: 98/07832 (1998-02-01), None
patent: WO 98/33917 (1998-08-01), None
patent: 99/33485 (1999-08-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 2004/009773 (2004-01-01), None
Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. □□ Identification of a new endothelial cell growth factor receptor tyrosine kinase.□□Oncogene. Sep. 1991;6(9):1677-83.
Mickle JE et al. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am. May 2000;84(3);597-607.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234.
Yan et al., Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290: 523-527, 2000.
Achen, M. G., et al., “Localization of Vascular Endothelial Growth Factor-D in Malignant Melanoma Suggests a Role in Tumour Angiogenesis,” J. Pathol. 193(2):147-54 (2001).
Achen, M.G. et al., “Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3,”Eur. J. Biochem, 267(9):2505-15 (May, 2000).
Achen, M.G. et al., “Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci., USA, 95(2):548-553 (Jan., 1998).
Akagi, K., et al., “Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues,”Br. J. Cancer, 83(7):887-91 (Oct., 2000).
Andre, T., et al., “Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa,”Int. J. Cancer, 86(2):174-81 (Apr. 15, 2000).
Andersson et al., “Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines,” In R. F. Revoltella (ed.),Expression of Differentiated Functions in Cancer Cells. 239-245, Raven Press, New York (1982).
“Angiogenesis Inhibitors in Cancer Research,”Cancer Trials, at cancertrials.nci.nih.gov
ews/angio/fsangio/fsangio.html (visited Jan. 24, 2001).
“Angiogenesis Inhibitors in Clinical Trials,”Cancer Trials, at cancertrials.nci.nih.gove
ews/angio/table.html (visited Jan. 24, 2001).
“Angiogenesis Inhibitors in Clinical Trials,”Cancer Trials, at cancertrials.nci.nih.gove
ews/angio/table.html (visited Sep. 25, 2001).
“Angiogenesis Inhibitors in Clinical Trials: Expanded Trial Information,”Cancer Trials, at cancertrials.nci.nih.gove
ews/angio/table.html (visited Sep. 25, 2001).
Aprelikova et al., “FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter,”Cancer Research, 52(3):746-748 (Feb. 1, 1992).
Aujame, L. et al., “High affinity human antibodies by phage display,”Human Antibodies, 8(4):155-168 (1997).
Banerji, S. et al., “LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan,”J Cell Biol. 144(4):789-801 (1999).
Beckstead, J.H. et al., “Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium,”Am. J. Pathol., 119(2):294-300 (May, 1985).
Benz, C. C. et al., “Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2
eu,”Breast Cancer Res Treat. 24(2):85-95 (1993).
Berridge et al., “Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIIa Glycoprotein Complex,”Blood, 66(1):76-85 (Jul., 1985).
Bolen, J.B., “Nonreceptor Tyrosine Protein Kinases,”Oncogene, 8:2025-2031 (1993).
Bolhuis, R.L. et al., “T cell targeting in cancer therapy,”Cancer Immunology Immunotherapy, 34(1):1-8 (1991).
Borg et al., “Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase,”Oncogene, 10:973-984 (1995).
Brown, L.F. et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer,”Human Pathology 26(1):86-91 (Jan., 1995).
Brü{umlaut over ( )}ggemann, M. et al., “Production of human antibody r

Affiliated with

Also associated with

Rating

FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3583701